HUMANA INC Q3 FY2026 earnings call

• Strategic Execution & Outlook: Management reports strong execution with results moving from 'on plan' to 'ahead of plan.' The strategy is validated by tangible improvements in member health outcomes, margins, and earnings growth.
• Medicare Advantage (MA) Product & Experience: 2026 membership retention and new sales are performing in line to better than expected. 2027 product positioning is aligned with bids. Autumn Enrollment Period (AEP) performance is ahead of expectations, with strong recapture of members impacted by competitor plan exits. Membership for 2027 is anticipated to grow.
• Clinical Excellence (Star Ratings): Bonus Year 28 (BY28) Star ratings achieved a member-weighted score of 4.17, approaching Humana’s historical highs. This resulted in significant clinical detections, including 600 undetected breast cancers and 100 pre-cancers/cancers via colorectal screenings. BY29 performance is tracking roughly 5% ahead of last year’s improvement rate, with confidence in achieving top quartile.
• Operational Efficiency: Multi-year operational transformation is progressing as anticipated. Cost trends for both new and existing members are in line to better than expected. Inpatient costs and Part D costs are showing favorability.
• Capital Allocation & Growth:
  • Medicaid: Expanded footprint to 13 states (11 active). Membership grew by 104,000 in 2026, driven by integrated dual eligible programs in Michigan, Illinois, and South Carolina.
  • CenterWell Primary Care: Added nearly 147,000 members (30% growth), aided by the MaxHealth acquisition. Established a new joint venture with BlackRock to enhance balance sheet efficiency.
  • Balance Sheet: Divestment of Gentiva minority interest yielding ~$900 million pre-tax proceeds. New BlackRock JV reduces cost of capital and GAAP debt-to-cap ratio by ~130 basis points.

The provided transcript does not contain specific financial performance data (revenue or profit figures) broken down by individual product segments such as Medicare Advantage, Medicaid, or CenterWell. Management discusses aggregate performance trends and margin improvements across the enterprise rather than providing segment-specific absolute or percentage contribution metrics.

• Full-Year EPS: Increased adjusted EPS outlook from at least $9.00 to at least $9.50.
• 2027 MA Margin: Anticipates meaningful progress and material improvement in individual MA margins (both STARS-adjusted and unadjusted), targeting profitability well into the range despite carrying a STARS headwind.
• 2028 Margin Target: Portfolio positioned to deliver margin progression necessary to achieve a 3%+ margin in 2028.
• STARS Performance: Expecting to sustain top quartile performance for Bonus Year 29 (BY29). Acknowledges a one-time tailwind in 2028 due to exceeding top quartile goals, which will be partially reinvested and partially returned to shareholders.
• Cost Trends: Expects medical trend to increase to 8-9% for the coming year, driven largely by a 14-15% increase in Part D costs due to the health technology pipeline.

• Regulatory & Competitive Dynamics: Future guidance and tailwind quantification depend on competitive dynamics, membership composition, and the regulatory environment.
• Operational Capacity Limits: There may be limitations on the ability to productively invest all excess STARS earnings; management must balance reinvestment against shareholder returns.
• Provider Network Pressure: Specific geographic pressures in Florida involving outlying facilities have impacted costs, though management believes these have been ring-fenced and addressed through contracting and network management actions.
• Cost Trend Uncertainty: While current trends are favorable, future years face higher cost pressures, particularly in Part D and medical services, requiring careful pricing discipline.

Q: Analyst asked for details on 2027 MA margin headwinds/tailwinds and expectations for margin expansion. / A: CFO stated there are no known incremental headwinds beyond the current STARS headwind. Tailwinds include ongoing OpEx/medical cost reductions via care outcomes, moving through Medicaid/PCO J-curves, improved product pricing, and lower new-member marketing/onboarding costs. She expects material improvement in both STARS-adjusted and unadjusted margins, though precise landing spots depend on final membership size and ADP mix.

Q: Analyst requested color on cost trends for 2027 and specifics on PCO cost pressures. / A: CFO noted current cost trends are at the low end of the 7-8% range, favoring inpatient and Part D sides. For 2027, trends are expected to rise to 8-9%, driven by a 14-15% increase in Part D costs from health tech pipelines. Regarding PCO, she acknowledged pressure in one geography but stated that CenterWell and payer partners have taken action (contracting changes, benefit design, network management) to mitigate most of the impact.

Q: Analyst asked about 2027 MA membership growth expectations and competitive AEP surprises. / A: CEO Jim Rechtin highlighted that outperformance is driven by stronger distribution channel partners following quality improvements made a year ago. He confirmed membership growth for 2027 but declined to provide a specific numerical range due to lack of retention data. CFO added that larger players appear better positioned than expected given competitor plan exits and some market consolidation.

Q: Analyst asked how management plans to split the excess STARS earnings (tailwind) between investment and shareholder returns. / A: CEO explained that the exact tailwind size cannot be quantified until late next year, depending on competitor actions, membership mix, and operational capacity to invest. He emphasized that while they will invest in areas increasing enterprise value, they will not spend money just to spend it. Consequently, a portion will inevitably pass through to earnings/shareholders, but the split will be determined after assessing productive investment opportunities over the next 12 months.

Q: Analyst asked about the shift from managing to 90% four-star rates to managing for top quartile, and future value-based care percentages. / A: CEO clarified that the goal remains to be the best (top decile), but they now manage their cost and benefit structures based on top quartile sustainability to enforce discipline. This ensures the business model survives even if stars dip slightly. CFO added that they are shifting focus from pure risk-sharing to aligning with high-quality providers, regardless of whether they take risk. They prioritize quality outcomes over simply increasing the percentage of providers in value-based arrangements.